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PHeart Rhythm Disorders
Results of a Multicenter Retrospective
Implantable Cardioverter-Defibrillator Registry
of Pediatric and Congenital Heart Disease Patients
Charles I. Berul, MD,* George F. Van Hare, MD,†‡ Naomi J. Kertesz, MD,§ Anne M. Dubin, MD,†
Frank Cecchin, MD,* Kathryn K. Collins, MD,‡ Bryan C. Cannon, MD,§ Mark E. Alexander, MD,*
John K. Triedman, MD,* Edward P. Walsh, MD,* Richard A. Friedman, MD§
Boston, Massachusetts; Palo Alto and San Francisco, California; and Houston, Texas
Objectives We sought to determine the implications of implantable cardioverter-defibrillator (ICD) placement in children
and patients with congenital heart disease (CHD).
Background There is increasing frequency of ICD use in pediatric and CHD patients. Until recently, prospective registry enroll-
ment of ICD patients was not available, and children and CHD patients account for only a small percentage of
ICD recipients. Therefore, we retrospectively obtained collaborative data from 4 pediatric centers, aiming to iden-
tify implant characteristics, shock frequency, and complications in this unique population.
Methods Databases from 4 centers were collated in a blinded fashion. Demographic information, implant electrical pa-
rameters, appropriate and inappropriate shock data, and complications were recorded for all implants from
1992 to 2004.
Results A total of 443 patients were included, with a median age of 16 years (range 0 to 54 years) and median weight
of 61 kg (range 2 to 130 kg), with 69% having structural heart disease. The most common diagnoses were te-
tralogy of Fallot (19%) and hypertrophic cardiomyopathy (14%). Implant indication was primary prevention in
52%. Shock data were available on 409 patients, of whom 105 (26%) received appropriate shocks (mean 4
shocks/patient, range 1 to 29 shocks/patient). Inappropriate shocks occurred in 87 of 409 patients (21%),
with a mean of 6 per patient (range 1 to 60), mainly attributable to lead failure (14%), sinus or atrial tachy-
cardias (9%), and/or oversensing (4%).
Conclusions Children and CHD ICD recipients have significant appropriate and inappropriate shock frequencies. Optimizing
programming, medical management, and compliance may diminish inappropriate shocks. Despite concerns re-
garding generator recalls, lead failure remains the major cause of inappropriate shocks, complications, and sys-
tem malfunction in children. Prospective assessment of ICD usage in this population may identify additional im-
portant factors in pediatric and CHD patients. (J Am Coll Cardiol 2008;51:1685–91) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.033p
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smplantable cardioverter-defibrillator (ICD) therapy was
ntroduced in the 1980s, and over the past few decades, it
as been used with increasing frequency in children and
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eart Foundation. This study was approved and facilitated by the Pediatric and
ongenital Electrophysiology Society (PACES).s
Manuscript received September 10, 2007; revised manuscript received January 16,
008, accepted January 26, 2008.atients with congenital heart disease (CHD). Advances in
echnology have allowed downsizing of devices and leads,
aking them more suitable for application in children.
ntil recently, prospective enrollment of ICD patients in a
ational registry was not available, and children and CHD
atients account for only a very small percentage (1%) of
ll ICD recipients. Therefore, we sought to retrospectively
btain collaborative data from 4 pediatric ICD implanting
enters, aiming to identify implant characteristics, shock
requency, and long-term complications in this unique
atient population. There have been prior pediatric reports
f ICD use in children, mainly involving either mining and
ubset extraction from manufacturers’ databases or relatively
mall single-center descriptive reports (Table 1) (1–14).
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Multicenter Pediatric ICD Registry April 29, 2008:1685–91One collaborative study pub-
lished in 1993 from members of
the Pediatric Electrophysiology
Society (1) initially contacted
manufacturers to identify pa-
tients under 20 years of age and
then obtain additional clinical
details on 125 of these early-era
CD patients from their physicians. These clinical series
ighlight some of the unique issues related to patient
election, implantation techniques, programming, and com-
lications in this population. The purpose of the present
tudy is to examine a current-era cohort using a long-term
ulticenter retrospective approach to identify a large group
f pediatric and CHD patients with ICDs.
ethods
atabases from 4 centers were reviewed and collated in a
linded fashion for review by the investigators. Local
nvestigational review board approval was obtained at each
ite. Two of the centers were combined because they had
verlapping physician implanters and to allow adequate
ubgroup sample size. The databases were queried for
ediatric and adult CHD patients with ICDs implanted
etween March 1992 and March 2004 to allow sufficient
ime after device implantation for observation of shocks and
omplications. Demographic information, implant electrical
arameters, appropriate and inappropriate shock data, and
omplications were recorded for all implants occurring
ithin the specified time frame. Demographics included
atient age, weight, gender, anatomic diagnosis, and elec-
rical diagnosis. The implant data included type of ICD,
ype of lead, indication for implant, electrical parameters,
nd defibrillation threshold when available. The indications
Abbreviations
and Acronyms
CHD  congenital heart
disease
ICD  implantable
cardioverter-defibrillator
revious Pediatric ICD Retrospective Series
Table 1 Previous Pediatric ICD Retrospective Series
First Author
(Ref. #)
Year
Published No. of Patients Study Type
Silka (1) 1993 125 Manufacturers’
datasets and
multicenter
retrospective
Kron (2) 1994 17 Manufacturers’
datasets
Hamilton (3) 1996 11 Single-center
Link (4) 1999 11 (vs. 309 adults) Single-center
Stefanelli (5) 2002 27 Single-center
Alexander (6) 2004 76 (included here) Single-center
Gradaus (7) 2004 25 Single-center
Goel (8) 2004 12 Single-center
Werner (9) 2004 7 Single-center
Korte (10) 2004 20 Single-center
Ten Harkel (11) 2005 23 Multi-center
Apitz (12) 2006 12 Single-center
Eicken (13) 2006 16 Single-center
Kaski (14) 2007 22 Single-centeriCD  implantable cardioverter-defibrillator.or implantation and other implant data were determined
ontemporaneously at each center from available records at
ime of implant and were then retrospectively adjudicated by
hart review. The shock data included the receipt of any
hocks (whether appropriate or inappropriate), number
f shocks per episode, number of episodes shocked, time of
hock since ICD implanted, and whether the shock was
uccessful at converting rhythm. Shock data were also assessed
y era of implant, divided into 2 equal groups. In addition,
hock data were subanalyzed by implanting center to investi-
ate variances in implant indications. Complications were
ompiled by time since implant and divided into acute (within
0 days of ICD implant) and chronic complications.
tatistics. Continuous variables were expressed as medians
nd ranges. Comparisons between medians were made with
he Wilcoxon rank-sum test. Event data (shock frequency)
ere analyzed using the chi-square or Fisher exact test
epending on sample size. Multivariable analysis (compar-
sons between centers) used analysis of variance, with
cheffe’s subgroup testing where appropriate. A value of p 
.05 was considered significant for individual comparisons.
esults
emographics. Over the 12-year study period, a total of
43 patients were included, with a median age of 16 years
mean age 18 years, range 0 to 54 years) and median weight
f 61 kg (mean 61.3  22.9 kg, range 2 to 130 kg). The
ean height of subjects at time of first ICD implant was
60.7  21.3 cm, and mean body surface area was 1.64 
.4 m2. A total of 307 patients (69%) had structural heart
isease, including various types of CHD (46%) or cardio-
yopathy (23%) (Fig. 1). The most common structural
iagnoses seen were tetralogy of Fallot (19%) and hypertro-
hic cardiomyopathy (14%). Primary electrical diseases with
structurally normal heart, such as long-QT syndrome,
rugada syndrome, and catecholaminergic polymorphic ven-
ricular tachycardia, accounted for 31% of patients (Fig. 2).
here were 7 infants who underwent first ICD implantation
t 1 year of age (Table 2). Adult patients (age 21 years)
ccounted for 111 of 443 patients (25%) and, not surpris-
ngly, were much more likely to have CHD (n  96; 86%)
ompared with dilated or hypertrophic cardiomyopathies (n
11) or primary electrical diseases (n  4).
mplant characteristics. The indications for ICD implan-
ation were primary prevention in 231 patients (52%) and
econdary prevention in 212 patients (48%). There was
ome variation in implant indications between centers and
ver time, with primary prevention indications more prev-
lent in the recent era (years 2000 to 2004) compared with
he first half of the study group (Fig. 3). The ICD generator
ype selected was single-chamber in 186 patients (42%) and
ual-chamber in 257 patients (58%). The defibrillator lead
ype was overwhelmingly active-fixation (429 patients, 97%),
ith only 14 patients receiving passive-fixation ICD leads atnitial implant. The leads were single-coil in 199 patients
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April 29, 2008:1685–91 Multicenter Pediatric ICD Registry45%) and dual-coil in 244 patients (55%). There were no
mplant procedure-related deaths.
hocks. APPROPRIATE SHOCKS. Defibrillation therapy for
ventricular arrhythmia faster than the programmed detec-
ion criteria, and accurately detected by the ICD, was
ategorized as an appropriate shock. Information regarding
hocks was available on 409 of 443 patients (92%) in the
atabases, of whom 105 patients (26%) received appropriate
Figure 1 Anatomic Diagnoses of Pediatric and Congenital
Implantable Cardioverter-Defibrillator Recipients
Congenital heart disease (CHD) accounts for 46% of total, cardiomyopathies
(CM) 23%, and structurally normal hearts (NL) with primary electrical diseases
accounting for 31% of all patients. Among CHD patients, diagnoses included
tetralogy of Fallot (TOF), transposition of great arteries (TGA), atrial and/or ven-
tricular septal defects, valve abnormalities, single ventricle, Shone’s complex,
coronary artery congenital anomalies, Ebstein anomaly of tricuspid valve, and
others. Cardiomyopathies included hypertrophic cardiomyopathy (HCM), dilated
cardiomyopathy (DCM), arrhythmogenic right ventricular dysplasia/cardiomyopa-
thy (ARVC), left ventricular noncompaction (LVNC), and restrictive cardiomyopa-
thy (RCM).
Figure 2 Electrical Diagnoses of Pediatric ICD
Recipients With Structurally Normal Hearts
The majority of patients with primary electrical diseases had long-QT syndrome
(LQTS). Smaller subgroups included idiopathic (idio) ventricular fibrillation (VF),
catecholaminergic polymorphic ventricular tachycardia (CPVT), ventricular tachy-
cardia (VT) not otherwise specified (NOS), conduction system disease (cond
sys dz), and Wolff-Parkinson-White (WPW) syndrome with atrioventricular block
(AVB). ICD  implantable cardioverter-defibrillator.hocks, at a mean of 4 shocks per patient (median 2, range
to 29). Appropriate shocks were more common in patients
ho received an ICD for secondary prevention (32%)
ompared with primary prevention (18%, p  0.001).
lthough most patients who received an appropriate shock
id so within the first 5 years, 7 patients (7%) did not receive
shock until after receiving their second ICD generator at
mean of 5.5 years after their initial ICD implantation.
hen evaluation was between implant eras, appropriate
hocks occurred more commonly among those implanted
rom 1992 to 1999 (35%) compared with 2000 to 2004
20%, p  0.05). Obviously, this difference is at least
artially accounted for by the differences in length of
ollow-up between the 2 cohorts, as well as differences in
mplant indications and disease severity. These trends for
mplant indication and implant era were similar among all
f the individual study centers (Fig. 4).
In an attempt to distinguish clinical differences between
hildren and adult congenital ICD patients, the shock
requency was analyzed by age. Overall, appropriate shocks
ere observed in 66 of 290 (23%) pediatric patients (age
18 years) and in 39 of 119 (33%) patients over age 18 years
n this cohort (p  0.05, chi-square test). There were no
ifferences seen in subgroup testing among different diag-
ostic categories (primary electrical diseases vs. congenital
ge at First ICD Implantation
Table 2 Age at First ICD Implantation
Age (yrs) CHD EM CM Total
1 2 2 3 7 (1.5%)
1–5 4 12 3 19 (4.2%)
6–10 9 30 14 53 (12%)
11–15 35 55 56 146 (33%)
16–21 48 35 24 107 (24%)
21 96 4 11 111 (25%)
otals are number of patients and percentages of total.
CHD  congenital heart disease; CM  cardiomyopathy; EM  electrical myopathy; ICD 
mplantable cardioverter-defibrillator.
Figure 3 Indications for Implantable Cardioverter-
Defibrillator Implantation, Overall and by Era
There is a significant change in the ratio of primary to secondary prevention
indications over time between eras (*p  0.002 for prevention type by era).
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Multicenter Pediatric ICD Registry April 29, 2008:1685–91eart disease vs. cardiomyopathies) for either pediatric or
dult patients.
NAPPROPRIATE SHOCKS. Defibrillation therapy received
Figure 4 Shock Frequency by Center and Era
The 2 California centers were combined and analyzed as 1 center because they
merged electrophysiology programs with overlapping implanting physicians, and
also to allow adequate sample size. Appropriate shock frequency by center (top
panel) and by era of initial device implantation (middle panel). Overall, secondary
indications patients are more likely to have received an appropriate shock than
those implanted for primary indications (32% vs. 17%, p  0.001); however, there
were no significant differences between centers. Appropriate shocks were more
common in patients implanted in the earlier era (p  0.05), regardless of indica-
tion type. Inappropriate shock frequency by center and overall (bottom panel). The
proportion of inappropriate shocks does not differ for primary and secondary indi-
cations, and there is no significant difference (p  0.05) between centers. Center
A had a trend toward less inappropriate shocks in secondary indications, but this
was also not statistically significant.or anything other than a ventricular arrhythmia faster ohan the programmed detection criteria was categorized
s an inappropriate shock. Inappropriate shocks occurred
n 87 of 409 patients (21%), with a mean of 6 inappro-
riate shocks per patient (median 4, range 1 to 60),
ainly attributable to lead failure (14%), sinus or atrial
achycardias (9%), and/or oversensing (4%). Inappropri-
te shocks occurred with similar frequency for primary
ersus secondary implant indications, and there were no
ifferences when analyzed by centers. When analyzed by
ge groups, 70 of 290 (24%) pediatric patients (age 18
ears) experienced at least 1 inappropriate shock, com-
ared with only 17 of 119 (14%) adult patients over 18
ears old (p  0.05, chi-square test). In pediatric sub-
roup analysis, an inappropriate shock was less likely to
ave been received in cardiomyopathy patients (13%)
ompared with primary electrical disease (31%) or con-
enital heart disease (28%) patients (p  0.01).
Following an inappropriate shock that was not related to
ead problems, specific clinical interventions included
) encouraging better compliance with medications such as
eta-blockers; 2) initiation of an antiarrhythmic medication;
) catheter ablation for atrial flutter; or 4) device reprogram-
ing, such as tachycardia detection rates, R-wave sensing,
lanking periods, and use of tachycardia discrimination
lgorithms. Multiple interventions were performed in some
f these patients (sometimes simultaneously), precluding
nalysis of the effect of specific changes. However, following
hese overall clinical management strategies, there were
ess frequent shocks among the cohort, particularly for sinus
achycardia, and the inappropriate shock frequency was mark-
dly reduced or eliminated for some individual subjects.
omplications. A total of 64 acute complications oc-
urred in 55 patients during the first 30 days after implant
Table 3). Of these, most directly resulted from the initial
mplantation surgery, such as lead placement issues,
nfections, bleeding, and vascular problems. The chronic
omplications were more difficult to fully ascertain, but at
east a lower boundary was identified, as not all follow-up
omplications may have been documented. The majority
f chronic complications related to lead issues, including
onductor fractures, insulation breaches, and changes in
lectrical characteristics. There was not any specific
anufacturer or model of lead that had a higher failure
ate in this series. In addition, there was no obvious trend
oward a difference in lead failure rates by subgroup
nalysis for lead type or approach (transvenous vs. epi-
ardial, subcutaneous, pericardial, or nonstandard im-
lants), although the number of patients with nonstand-
rd lead implant approaches was underpowered to
etermine statistical significance. There were no associ-
tions between specific manufacturers’ advisories and lead
ailures. Generator-related problems that necessitated
eoperation were notably uncommon, occurring in only 3
f 443 patients (0.68%) over the 12-year study period.
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April 29, 2008:1685–91 Multicenter Pediatric ICD Registryortality. Among the study cohort, there was a total of 18
eaths (4% all-cause mortality) during follow-up, of which
nly 4 (1%) were known to be sudden cardiac death or
ocumented fatal arrhythmia. The nonsudden deaths were
ttributed to progressive congestive heart failure, pulmonary
mbolism, cerebrovascular accident, or unknown (nonsud-
en) etiology. A total of 16 patients (3.6%) underwent
rthotopic heart transplant at some point following their
CD implantation. They did not receive a new ICD system
uring or following transplant, and 3 of these 16 patients
ubsequently died after transplantation.
iscussion
arge, prospective double-blinded trials to assess the safety
nd efficacy of ICD therapy in adults have proven the value
f ICDs in a variety of disease substrates, including post-
yocardial infarction, ischemia, and cardiomyopathies (15–
8). Implant indications and guidelines have been developed
CD-Related Complications
Table 3 ICD-Related Complications
No. of Complications
Acute Complications (Perioperative or Within 30 Days of Implant)
Lead dislodgement 13
Inability to defibrillate or unacceptable DFT 9
Bleeding or pocket hematoma 8
Infection 7
Unsuccessful transvenous lead placement 6
Electrical storm 5
Hemothorax or pneumothorax 4
EMD/PEA 4
Skin erosion 3
SVC syndrome 2
Skin burns 2
Pneumonia and ileus 1
Total acute complications 64 (in 55 patients)
Chronic Complications (More Than 30 Days After Implant)
Lead-related problems overall 68
Lead conductor fractures 20
Lead insulation breech 28
Lead late dislodgement 7
Lead-related change in capture, sensing, or DFT 13
Electrical storm 23
Inappropriate shocks (not related to lead failure) 22
Infection 13
Generator malfunction 2
Manufacturers’ advisories/FDA recalls – device failure 1
Total chronic complications 130 (in 116 patients)
Mortality
Periprocedural death 0
Death 30 days after implant 18 (4 known SCD)
Orthotopic heart transplantation after ICD 16
Death after orthotopic heart transplantation 3
FT  defibrillation threshold; EMD/PEA  electromechanical dissociation/pulseless electrical
ctivity; FDA  Food and Drug Administration; SCD  sudden cardiac death; SVC  superior vena
ava; other abbreviations as in Table 2.o appropriately determine who is a good ICD candidate for 2oth primary and secondary prevention (19,20). The sheer
olume of adult patients in these studies dwarfs the pediatric
CD experience, where sudden cardiac death is fortunately
elatively uncommon (except perhaps in untreated chan-
elopathies and malignant myocarditis/cardiomyopathies).
owever, the rarity of diseases and cardiac events also
akes determining the appropriate indications for therapy
iagnostically challenging. The impact of receiving an ICD
ay be more substantial in a young patient, who may live
or decades after initial device implantation and would be
ubject to multiple procedures for generator replacements
nd lead revisions/extractions (21,22). These additional
rocedures significantly increase the complexity of decision-
aking, increase costs, and likely increase psychosocial
tressors related to ICD therapy (23,24). In addition,
ssessing the safety and efficacy is hindered by the sample
ize necessary to achieve adequate statistical power, which
as previously limited the ramifications and conclusions of
rior pediatric ICD series.
The small retrospective series in pediatrics do suggest a
otential benefit to ICD therapy in children. Particularly in
atients implanted for secondary prevention, there is a high
eported rate of appropriate shocks, at least some of which
an be presumed to be lifesaving. Silka et al. (1) surveyed
embers of the Pediatric Electrophysiology Society in the
arly 1990s regarding their ICD patients, and reported 125
atients under age 20 years implanted with an ICD,
redominantly following resuscitated sudden death (76%),
rug-refractory ventricular tachycardia (10%), or syncope in
atients with structural heart disease and inducible sustained
entricular tachyarrhythmias. This relatively early series of
ediatric ICD patients implanted before 1992 included a
reponderance of epicardial ICD systems, and they had a
igh appropriate shock rate (68% over 31  23 month
ollow-up). Interestingly, similar to recent adult studies, the
ain predictor of mortality among these patients was
mpaired ventricular function (1). Gradaus et al. (7) reported
survival benefit in children with ICDs by comparing the
ifference between the curves for death versus the combined
nd point of death plus recurrences of fast symptomatic
entricular tachycardia. However, despite a high rate of
ppropriate shocks for ventricular arrhythmias, 2 of 25
hildren died (including 1 death from ICD patch electrode
rosion), and they had a high rate of inappropriate shocks:
8% in the first year and 49% by 5 years of follow-up (7).
revious studies have shown a higher rate of complications
nd technical difficulties related to ICD implantation and
anagement in the pediatric population. A comparison
tudy by Link et al. (4) found a significantly higher
omplication rate in pediatric versus adult ICD recipients
mplanted at the same institution. In a smaller study, Goel
t al. (8) reported their experience with ICD therapy for
hildren with long-QT syndrome and observed appropriate
herapies in 5 of 12 patients, inappropriate shocks in 4 of 12,complications, and 1 death after electrical storm. Korte
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Multicenter Pediatric ICD Registry April 29, 2008:1685–91t al. (9) categorized shocks in pediatric ICD recipients as
ppropriate in 15 of 20 patients (75%) and inappropriate in
0 of 20 patients (50%), attributable mainly to supraven-
ricular tachycardia, T-wave oversensing, or lead failure.
lexander et al. (6) reported a 38% complication rate over
-year follow-up in 76 pediatric and young adult ICD
atients (who are included in the present series), including
nfection, lead failure, and potential for electrical storm. In
hat study, growth was strongly associated with lead failure,
ith a change in body surface area having the highest hazard
atio. Eicken et al. (13) reviewed 16 patients who received
n ICD and found 7 of the 16 (44%) received appropriate
herapies, whereas 4 (25%) received inappropriate shocks. In
recent study including 22 children with hypertrophic
ardiomyopathy who received an ICD (14), only 4 (18%)
eceived appropriate shocks, and 4 also received 1 or more
nappropriate shocks; complications were reported for 3 of
2 patients. Increased recognition of the risks of ICD lead
ractures and inappropriate shocks have led to the develop-
ent of novel implantation techniques and leadless ICD
ystems for small children and patients with complex
ongenital heart disease (25–27). Several investigators
27,28) have described subcutaneous coil placement around
he heart, as well as in the pericardium.
The present multicenter retrospective study demonstrates
he heterogeneity of pediatric and congenital heart ICD
ecipients and highlights important issues related to growth
nd development. The results from this study confirm that
hildren and CHD patients who are ICD recipients have
ignificant appropriate and inappropriate shock frequencies.
ith 105 patients (26%) receiving a mean of 4 appropriate
hocks each, it is highly probable that at least some of these
hocks were potentially lifesaving, although the study design
oes not allow a determination of hemodynamic compro-
ise from the ventricular arrhythmias or the impact of
CDs on overall survival benefit. However, the overall
ll-cause mortality rate of 4% and sudden cardiac death rate
f 1% over a relatively long follow-up period (mean 7.5
ears, range 1 to 20 years) were strikingly low compared
ith similar adult ICD patient series (15–17). This finding
ubstantiates the perceived concerns regarding the long-
erm impact of receiving an ICD and exposure to chronic
evice-related and procedure-related complications such as
ead failure and extraction.
The relatively high rate of inappropriate shocks and
omplications, similar to that observed in smaller pediatric
eries, increases the morbidity of ICD therapy in children,
alancing the risk-benefit ratio. The finding of higher
nappropriate shock rates in children versus adults with
ongenital heart disease supports the hypothesis that con-
inued growth and activity place increased strain on ICD
eads, rather than the alternative that the congenital heart
isease is a primary risk factor. Therefore, clarification of
roper indications for implantation is critical for determin-
ng the optimal pediatric candidates for ICD therapy. We
uggest that careful attention to optimizing device program-ing, medical management, and encouraging compliance
ith prescribed therapies and recommendations may dimin-
sh inappropriate shock frequency in this unique patient
opulation.
tudy limitations. The limitations of this retrospective
ulticenter study include practice variations between cen-
ers; differences in implant threshold and indications for
CD; variations between operators in implantation tech-
iques and programming; and variances in case mix, ages,
resence, and complexity of CHD. The follow-up design
id not capture the time to each appropriate shock for all
atients, limiting the ability to perform a time-dependent
nalysis of ICD therapies. Finally, although shock data was
etermined for 92% of subjects, the chronic follow-up and
ate complications are likely not comprehensively reported
or all patients.
onclusions
his is the largest series of pediatric and congenital heart
CD patients reported to date. It is a heterogeneous group
ith a wide age range (infant through adult) and broad mix
f diagnoses. The threshold for prescribing an ICD in the
ediatric and congenital heart population appears to have
owered over time. The indications for implantation are
learly different from most adult ICD series, which have a
reponderance of ischemic heart disease and post-infarction
atients. Despite these differences, young ICD patients have
significant rate of shocks, both appropriate and inappro-
riate. However, although recent concerns regarding ICD
enerator recalls and manufacturers’ advisories have gener-
ted significant public concern (29,30), lead failure actually
emains the dominant mode of inappropriate shocks, com-
lications, and system malfunction in children. Future
irections that may identify additional important factors
nclude a prospective pediatric ICD registry and consensus
evelopment of guidelines and definitions in pediatric and
ongenital heart ICD recipients.
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